GlassScriptPhysician profile
Felipe A Arias
NPI 1124055371
$65,824.69
in general payments reported to CMS, 2019-2025
33 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $9,406 · 2021: $2,051 · 2022: $2,682 · 2023: $370 · 2024: $49.04 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $56,041.40 | 2019-2025 | Yeztugo |
| Merck Sharp & Dohme LLC | $4,440.73 | 2019-2022 | |
| Viiv Healthcare Company | $1,306.36 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Amarin Pharma, INC. | $759.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $592.60 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $362.72 | 2021-2022 | |
| Lilly USA, LLC | $263.31 | 2019-2022 | |
| Abbvie INC. | $236.53 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.05 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.98 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $147.75 | 2019-2022 | |
| Janssen Biotech, INC. | $143.50 | 2023 | Prezcobix, Symtuza |
| Glaxosmithkline, LLC. | $135.35 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $109.50 | 2022 | |
| Theratechnologies INC. | $108.10 | 2019-2025 | Trogarzo, Egrifta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $98.07 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $85.01 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $77.35 | 2021 | |
| Amgen INC. | $67.90 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.34 | 2022 | |
| Novartis Pharmaceuticals Corporation | $60.43 | 2019-2021 | |
| Alkermes, INC. | $48.84 | 2019-2024 | Vivitrol |
| Sunovion Pharmaceuticals INC. | $47.22 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $37.10 | 2023-2025 | Rexulti |
| Indivior INC. | $36.86 | 2021 | |
| Mdd US Operations, LLC | $27.56 | 2019 | |
| Exact Sciences Corporation | $25.66 | 2025 | Cologuard Collection Kit |
| Bausch Health US, LLC | $22.82 | 2019 | |
| Napo Pharmaceuticals INC | $20.91 | 2023 | Mytesi |
| Abbott Laboratories | $17.14 | 2021 | |
| Intra-Sana Laboratories | $13.70 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Astellas Pharma US INC | $13.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felipe Arias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.